ArticleActa dermato-venereologica2020
Disease and Treatment Characteristics in Geriatric Psoriasis: A Patient Survey Comparing Age Groups.
Article in Acta dermato-venereologica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Predictors of clinical response to biologics in psoriasis: A systematic review and meta-analysis.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Pooled it
- Efficacy and Safety of Tildrakizumab in Elderly Patients With Psoriasis: A Narrative Review.The Journal of clinical and aesthetic dermatology · 2026Review
- Biologic therapy in geriatric psoriasis: 6-month real-world data on PASI, inflammatory indices, and hepatitis B/tuberculosis safety.Biomolecules & biomedicine · 2026Article
- Biologic Treatment in Elderly Patients with Psoriasis: Focus on Safety and Adherence.Dermatology practical & conceptual · 2026Article
- Analysis of Clinical Characteristics and Treatment Needs in Elderly Patients with Psoriasis Vulgaris: A Single-Centered Retrospective Study.Clinical, cosmetic and investigational dermatology · 2026Article
- Exploring the Efficacy, Safety, and Clinical Implications of Deucravacitinib in East Asians with Psoriasis: A Narrative Review.Journal of clinical medicine · 2025Review
- Geriatric Psoriasis: Evaluation of Clinical Features, Disease Course, and Treatment Modalities of Patients from a Tertiary Care Hospital.Dermatology practical & conceptual · 2025Article
- Aging Impact in Response to Different Classes of Biological Treatment in Psoriatic Patients: A Real-Life Observational Study.Journal of clinical medicine · 2023Article
- Efficacy and Safety of Secukinumab in Elderly Patients with Moderate to Severe Plaque-Type Psoriasis: Post-Hoc Analysis of the SUPREME Study.Clinical, cosmetic and investigational dermatology · 2023Article
- Safety Assessment of Conventional and Biological Systemic Therapy in Older Adults with Psoriasis, a Real-world Multicentre Cohort Study.Acta dermato-venereologica · 2022Article
- Drug Survival, Safety, and Effectiveness of Biologics in Older Patients with Psoriasis: A Comparison with Younger Patients-A BioCAPTURE Registry Study.Drugs & aging · 2022Observational
- Discovery of Psoriatic Arthritis in Psoriasis Patients for Early Rheumatological Referral (DAPPER) Study: A Prospective Observational Cohort.Acta dermato-venereologica · 2022Observational
- Quality of life, treatment goals, preferences and satisfaction in older adults with psoriasis: a patient survey comparing age groups.The British journal of dermatology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Little is known about psoriasis in geriatric patients, whereas treating this growing population can be challenging due to comorbidities, comedication and physical impairments. To compare disease and treatment characteristics of psoriasis patients ≥ 65 years old with patients < 65 years old, a self-assessment survey was sent to all members of the Dutch Psoriasis Association (n = 3,310). In total, 985 (29.7%) patients returned the survey, 414 (43.6%) respondents were ≥ 65 years old. Patients ≥ 65 years old had experienced erythrodermic psoriasis significantly more frequently than patients < 65 years old, other disease characteristics were highly comparable. Despite a significantly higher prevalence of comorbidities and comedication use in patients ≥ 65 years old, no difference was seen between the age groups regarding systemic antipsoriatic treatment (38.3% in ≥ 65 years old vs 42.3% in < 65 years old; p = 0.219). Remarkably, treatment-related side-effects were reported more frequently by patients < 65 years old. In conclusion, age alone should not be a limiting factor in psoriasis management, and proper attention must be paid to additional patient-related factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.